Annie D. Niehaus

Annie D. Niehaus

Auto-generated profile, based on publicly available information

Annie D. Niehaus

Division of Medical Genetics, Department of Pediatrics Stanford School of Medicine Stanford California USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Genetics in Medicine
Verified
Journal Article
Open access
JHJessica Ezzell Hunter
Jessica Ezzell Hunter
SIStephanie A Irving
Stephanie A Irving
LBLeslie G Biesecker
Leslie G Biesecker
Adam H BuchananAdam H Buchanan
Adam H Buchanan
BJBrian Jensen
Brian Jensen
KGKatrina A B Goddard
Katrina A B Goddard
Genome and exome sequencing can identify variants unrelated to the primary goal of sequencing. Detecting pathogenic variants associated with an increased risk of a medical disorder enables clinical interventions to improve future health outcomes in patients and their at-risk relatives. The Clinical Genome Resource, or ClinGen, aims to assess clinical actionability of genes and associated disorders as part of a larger effort to build a central resource of information regarding the clinical relevance of genomic variation for use in precision medicine and research. We developed a practical, standardized protocol to identify available evidence and generate qualitative summary reports of actionability for disorders and associated genes. We applied a semiquantitative metric to score actionability. We generated summary reports and actionability scores for the 56 genes and associated disorders recommended by the American College of Medical Genetics and Genomics for return as secondary findings from clinical genome-scale sequencing. We also describe the challenges that arose during the development of the protocol that highlight important issues in characterizing actionability across a range of disorders. The ClinGen framework for actionability assessment will assist research and clinical communities in making clear, efficient, and consistent determinations of actionability based on transparent criteria to guide analysis and reporting of findings from clinical genome-scale sequencing.Genet Med 18 12, 1258-1268.

2 September 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
ANAnnie D. Niehaus
Annie D. Niehaus
JKJenny Kim
Jenny Kim
MMMelanie A. Manning
Melanie A. Manning

26 June 2024 in Genes
Verified
Journal Article
Open access
PDF file
CBCarlos Francisco Mares Beltran
Carlos Francisco Mares Beltran
CTChristina Gayle Tise
Christina Gayle Tise
RBRebekah Barrick
Rebekah Barrick
ANAnnie D. Niehaus
Annie D. Niehaus
RSRebecca Sponberg
Rebecca Sponberg
JAJose E Abdenur
Jose E Abdenur
The state of California (CA) added X-linked adrenoleukodystrophy (X-ALD) to newborn screening (NBS) in 2016 via the measurement of C26:0-lysophosphatidylcholine (C26:0-LPC) in a two-tier fashion, followed by sequencing of the ABCD1 gene. This has resulted in the identification of individuals with genetic conditions beyond X-ALD that can also result in elevated C26:0-LPC by NBS. We describe the biochemical, molecular, and clinical characteristics of nine patients from two metabolic centers in California who screened positive by NBS for elevated C26:0-LPC between 2016 and 2022 and were ultimately diagnosed with a genetic condition other than X-ALD. Seven individuals were diagnosed with Zellweger spectrum disorder (ZSD) due to biallelic variants in PEX genes. One male was diagnosed with Klinefelter syndrome and one female was found to have an X chromosome contiguous gene deletion syndrome after the identification of a heterozygous VUS and hemizygous VUS variant in ABCD1, respectively. Patients with ZSD had significantly higher first- and second-tier C26:0-LPC levels compared to the two non-ZSD cases. Identification of children with ZSD and atypical patterns of ABCD1 variants is a secondary benefit of NBS for X-ALD, leading to earlier diagnosis, prompt therapeutic initiation, and more accurate genetic counseling. As screening for X-ALD continues via the measurement of C26:0-LPC, our knowledge of additional genetic conditions associated with elevated C26:0-LPC will continue to advance, allowing for increased recognition of other genetic disorders for which early intervention is warranted.

2 March 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
ANAnnie D. Niehaus
Annie D. Niehaus
BMBryce A. Mendelsohn
Bryce A. Mendelsohn
BZBree Zimmerman
Bree Zimmerman
CLChung U. Lee
Chung U. Lee
MMMelanie A. Manning
Melanie A. Manning
CTChristina Gayle Tise
Christina Gayle Tise

1 January 2024 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
ANAnnie D. Niehaus
Annie D. Niehaus
HCHolly Cooper
Holly Cooper
CLChung U. Lee
Chung U. Lee
Here, we report an individual, eventually diagnosed with HMG-CoA synthase deficiency, who presented with a cyclic vomiting phenotype. HMG-CoA synthase deficiency is a rare disorder affecting ketone body synthesis in which affected individuals typically present at a young age with hypoketotic hypoglycemia, lethargy, encephalopathy, and hepatomegaly, usually triggered by catabolism (e.g., infection or prolonged fasting). This individual presented with recurrent episodes of vomiting and lethargy, often associated with hypoglycemia or hyperglycemia, at 3 years of age. Metabolic labs revealed nonspecific abnormalities in her urine organic acids (showing mild elevation of dicarboxylic acids with relatively low excretion of ketones) and a normal acylcarnitine profile. Given her clinical presentation, as well as a normal upper gastrointestinal series, esophagogastroduodenoscopy with biopsies, and abdominal ultrasound, she was diagnosed with cyclic vomiting syndrome at 3 years of age. Molecular testing completed at 7 years of age revealed a previously reported pathogenic sequence variant (c.1016+1G>A) and a novel likely pathogenic deletion (1.57 kB deletion, including exon 1) within HMGCS2 consistent with HMG-CoA synthase deficiency. This individual’s presentation, mimicking cyclic vomiting syndrome, widens the clinical spectrum of HMG-CoA synthase deficiency. In addition, this case highlights the importance of molecular genetic testing in such presentations, as this rare disorder lacks specific metabolic markers.

28 May 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
ANAnnie D. Niehaus
Annie D. Niehaus
CRCaroline E. Rassbach
Caroline E. Rassbach
DSDavid A. Stevenson
David A. Stevenson